ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation            | Nghiem, Paul, Peter K. Park, Yong-son Kim, Bimal N. Desai, and Stuart L. Schreiber. 2001. “ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint.” Journal of Biological Chemistry 277 (6): 4428–34. https://doi.org/10.1074/jbc.m106113200. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Citable link        | http://nrs.harvard.edu/urn-3:HUL.InstRepos:41467411                                                                                                                                                                                                                                                                               |
| Terms of Use        | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA                                                                                                                                 |
ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint*

Received for publication, July 1, 2001, and in revised form, August 21, 2001
Published, JBC Papers in Press, November 15, 2001, DOI 10.1074/jbc.M106113200

Paul Nghiem‡§§, Peter K. Park‡‡, Yong-son Kim‡‡‡, Bimal N. Desai, and Stuart L. Schreiber‡ ‡‡

From the §Department of Chemistry and Chemical Biology, Howard Hughes Medical Institute, Harvard University, Cambridge, Massachusetts 02138 and the ¶Cutaneous Oncology Unit, Dana-Farber Cancer Institute, Boston, Massachusetts 02115

ATR (ataxia telangiectasia and Rad-3-related) is a protein kinase required for survival after DNA damage. A critical role for ATR has been hypothesized to be the regulation of p53 and other cell cycle checkpoints. ATR has been shown to phosphorylate p53 at Ser15, and this damage-induced phosphorylation is diminished by expression of a catalytically inactive (ATR-kd) mutant. p53 function could not be examined directly in prior studies of ATR, however, because p53 was mutant or because cells expressed the SV40 large T antigen that blocks p53 function. To test the interactions of ATR and p53 directly we generated human U2OS cell lines inducible for either wild-type or kinase-dead ATR that also have an intact p53 pathway. Indeed, ATR-kd expression sensitized these cells to DNA damage and caused a transient decrease in damage-induced serine 15 phosphorylation of p53. However, we found that the effects of ATR-kd expression do not result in blocking the response of p53 to DNA damage. Specifically, prior ATR-kd expression had no effect on DNA damage-induced p53 protein up-regulation, p53-DNA binding, p21 mRNA up-regulation, or G1 arrest. Instead of promoting survival via p53 regulation, we found that ATR protects cells by delaying the generation of mitotic phosphoproteins and inhibiting premature chromatin condensation after DNA damage or hydroxyurea. Although p53 inhibition (by E6 or MDM2 expression) had little effect on premature chromatin condensation, when combined with ATR-kd expression there was a marked loss of the replication checkpoint. We conclude that ATR and p53 can function independently but that loss of both leads to synergistic disruption of the replication checkpoint.

The response to DNA damage is a complex process that is crucial in maintaining the fidelity of the genome amid diverse stresses. A conserved and critical aspect of this response is cell cycle arrest immediately following damage, which allows for DNA repair prior to progression. The mechanisms of arrest following DNA damage are becoming increasingly well understood and in many cases involve a member of a conserved family of very large protein kinases called the phosphatidylinositol kinase-related kinases (1, 2). In yeast, the Rad-3 (Schizosaccharomyces pombe) or Mec1 (Saccharomyces cerevisiae) family members are essential protein kinases that have been shown to be required for the response to diverse stresses including ultraviolet light, ionizing radiation, and hydroxyurea (3, 4). In humans, deficiency in ATM function leads to a complex phenotype including extreme sensitivity to ionizing radiation (IR),1 loss of p53 activation after IR, IR-resistant DNA synthesis, insulin resistance, chromosomal instability, loss of cerebellar neurons leading to ataxia, and development of lymphoid malignancies (5). The development of ATM-deficient mice and the human disease ataxia telangiectasia have led to a greater understanding of the functions of the ATM protein kinase.

The role of ATR (ataxia telangiectasia and Rad-3-related) has remained more mysterious than ATM because the ATR mouse is early embryonic lethal (6, 7), and there is no specific small molecule inhibitor for ATR. In particular, the role of ATR in regulating p53 function has remained unclear. Several studies have demonstrated that in vitro ATR phosphorylates p53 on serine 15 (8–11), a site that is phosphorylated in response to DNA damage and plays a role in its transcriptional activation (12). In addition, Tibbetts et al. (13) demonstrated that in cells overexpressing ATR-kd, this serine 15 phosphorylation did not occur normally in response to damage by ultraviolet light or ionizing radiation, implicating ATR in the regulation of p53 in cells. It is also plausible that ATR may regulate p53 indirectly via Chk-1. Several studies have documented that ATR activates Chk-1 (14–16), and Chk-1 has been shown to phosphorylate p53 (17). Moreover, p53 levels are decreased when Chk-1 is inhibited, suggesting that p53 expression may be regulated by Chk-1 (17). Importantly, these prior studies have not been able to examine the role of ATR in regulating p53 function or the induction of a G1 arrest because the p53 response was defective because of p53 mutations or expression of SV40 large T antigen, which binds p53 and blocks its function (18).

To address the role of ATR in DNA damage-induced p53 activation and G1 arrest, we generated U2OS-derived stable cell lines that can inducibly overexpress either wild-type or kinase-dead ATR and that are functional in p53 and G1 arrest pathways. Here we report our results using these cell lines that demonstrate that ATR is not required for p53 activation or G1 arrest and that ATR works together with p53 in the replication checkpoint to block cells from prematurely condensing their chromatin.

*This work was supported by National Institutes of Health Grant GM-52067. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¶ Supported by National Institutes of Health Grant K08-AR0208703.
‡ Supported by the Harvard College Research Program.
§ Supported by a Mildred Scheel Cancer Foundation Fellowship.
*‡ Investigator at the Howard Hughes Medical Institute. To whom correspondence should be addressed: Dept. of Chemistry and Chemical Biology, Howard Hughes Medical Inst., Harvard University, 12 Oxford St., Cambridge, MA 02138. E-mail: sls@slsiris.harvard.edu.

1 The abbreviations used are: IR, ionizing radiation; GFP, green fluorescent protein; PCC, premature chromatin condensation.
A TR and p53 in the G1 and Replication Checkpoints

EXPERIMENTAL PROCEDURES

Generation of Cell Lines—U2OS (human osteosarcoma) cells stably expressing the tetracycline repressor (Invitrogen) and verified to have intact p53 and G1 checkpoint function were used to generate doxycycline-inducible (19) stable cell lines. Amino-terminal FLAG epitope-tagged full-length constructs of ATR-wt or ATR-kd were inserted into the cytomegalovirus promoter-based plasmid pcDNA4/TO (Invitrogen), which contains two tetracycline operator-binding sites. These constructs were co-transfected with a 20-fold lower amount of pcDNA3.1, which contains the neomycin resistance gene. Beginning 2 days later, G418 (400 μg/ml)-resistant clones were selected. Hygromycin was always present at 200 μg/ml to maintain expression of the tetracycline repressor as described (19). Approximately 120 G418-resistant clones were screened by FLAG immunoprecipitation and FLAG Western blotting to contain two tetracycline operon-inducible vectors for ATR-wt or ATR-kd and that had undetectable expression of the FLAG-tagged protein in the absence of doxycycline induction.

DNA Damage—IR was delivered by Cesium-137 irradiation at a rate of 2.5 Grays/min. UV was delivered at a rate of 4 J/m²/s from a panel of four UV bulbs (8 watts/bulb, RPR-3000; Southern New England Ultra-violet Co., Branford, CT) that had peak emission at 312 nm. For UV irradiation, phenol-extracting media used to isolate total RNA, and 1 ml of this cell suspension was dropped from a height of 10 cm onto a glass coverslip. The discoloration of the coverslip was saved on ice, and the petri was extracted with two packed cell volumes of hypertonic buffer (10 mM Hepes, pH 7.6, 10 mM KCl, 1 mM MgCl₂, 1 mM diithiothreitol, 10% glycerol, 1 mM phenylmethylsulfonl fluoride), triturated with a pipetter, and placed on ice for 10 min. After centrifugation (at 12,000 × g for 5 min), the supernatant was saved on ice, and the pellet was extracted with two packed cell volumes of hypertonic buffer (hypotonic plus 500 mM KCl) for 30 min on ice after trituration. Nuclei were then spun at 12,000 × g for 5 min, and the supernatant was combined with the prior cytosolic extract. The DNA binding reaction was carried out at 23 °C for 30 min by adding 2.5 μl of a master mix containing 1 μl of diithiothreitol (50 mM stock), 1 μl of ZnCl₂ (500 μM stock), 1 μl of non-specific DNA (0.1 μg/μl, Bluescript plasmid DNA, digested with Hhal), 1 μl of probe (1 ng/ml of labeled, annealed, double-stranded DNA), 1.2 μl of glycerol, 0.5 μl of polyclonal antibody 421 (p53 Ab-1, 2 mg/ml, Oncogene), and 1.5 μl of Tri-buffered saline (25 mM Tris, pH 7.5, 130 mM NaCl, 3 mM KCl). The mixes were then applied and run on a 4% 4% nondenaturing polyacrylamide gel with 1% Tris-borate EDTA (with final EDTA of 1 mM to avoid gelating the zinc), and the gel was dried and exposed to film. Antibody 421 was induced because a signal in the absence of this antibody was poor in these cells, (b) no activation occurred merely by adding this antibody in the absence of damage, and (c) it is often included in gel shift studies of p53 function (22).

Cytometry/Cell Cycle Analysis—Unsynchronized ATR-kd-inducible U2OS cells were treated with doxycycline (1 μg/ml) for 48 h prior to UV treatment (200 J/m²) and nocodazole (100 ng/ml) as indicated. 16 h later cells were harvested, treated with trypsin and resuspended in 700 μl of phosphate-buffered saline, and 300 μl of ice-cold ethanol was added and mixed well. After at least 15 min on ice, the cells were spun at 300 × g, resuspended in 1 ml of RNase A in phosphate-buffered saline, and incubated at 37 °C for 30 min. The cells were spun at 300 × g and resuspended in 50 μg/ml propidium iodide in 0.1% sodium citrate. Flow cytometry was carried out on a FACScan (Becton Dickinson) apparatus as per the manufacturer's recommendations.

Double Thymidine Block—The cells were plated into normal medium, and after adhesion, 2.5 mM thymidine was added for 17 h. The cells were harvested, treated with trypsin and resuspended in 700 μl of phosphate-buffered saline, and 300 μl of ice-cold ethanol was added and mixed well. At least 15 min on ice, the cells were spun at 300 × g, resuspended in 1 ml of RNase A in phosphate-buffered saline, and incubated at 37 °C for 30 min. The cells were spun at 300 × g and resuspended in 50 μg/ml propidium iodide in 0.1% sodium citrate. Flow cytometry was carried out on a FACScan (Becton Dickinson) apparatus as per the manufacturer's recommendations.

Adenovirus-mediated Expression—Adenoviral constructs and virus preparations were performed as described (21). Purified virus was added to the cell medium to a final titer of 10¹⁰ viral particles/ml 24 h before UV treatment. Expression constructs were driven by the cytomegalovirus promoter, and protein expression was verified by Western blotting. Function of each protein was verified by flow cytometry for its expected cell cycle effects. Based on GFP expression performed in parallel, this concentration of 10¹⁰ viral particles/ml yielded 100% infection and expression in these cells.

Mitotic Spreads—Doxycycline was added on the day of plating. 24 h later, adenovirus was added as indicated to 10¹⁰ plaque-forming units/ml. 24 h later, the cells were treated with ionizing radiation or hydroxyurea, and all cells received nocodazole (100 ng/ml). 24 h later the cells were harvested with trypsin and spun (300 × g for 10 min). All but about 50 μl of supernatant was discarded, and the cells were resuspended with a pipetter. 1 ml of 75 mM KCl was added for 10 min at room temperature. The cells were spun, the supernatant was discarded, and the cells were resuspended in 300 μl of freshly prepared Carnoy's fixative (three parts methanol and one part glacial acetic acid) for 10 min at room temperature. The cells were spun, the supernatant was discarded, and the cells were resuspended in 100 μl of Carnoy's fixative. 10 μl of this cell suspension was dropped from a height of 10 cm onto a glass slide and allowed to dry. 12 μl of 4,6-diamidino-2-phenylindole solution (Vectashield with 4,6-diamidino-2-phenylindole, Vector Laboratories, Burlingame, CA) was spotted onto the slide, a coverslip was placed above it, and the edges were sealed with clear nail polish. A fluorescence microscope was used to count mitotic cells that had characteristic features of either diffuse or perinuclear condensation (PCC). Interphase cells and cells that were intermediate in morphology between normal and PCC were not counted. The following criteria were used to identify mitoses as PCC or normal. PCC characteristics include well defined particles of DAPI-staining material that were round, not oblong; space between the particles with no hazy chromatin material between particles; no chromatin-like pairs present;
and borders of the chromatin of the cell are jagged and composed of speckles, not smooth or with a creamy hazy appearance (all characteristics must be met to be counted). Normal mitosis characteristics include well formed oblong chromatids present in pairs and at least 20 such chromosome pairs found in a cluster.

RESULTS

ATR-inducible Cell Lines—Fig. 1 shows that these cell lines have several important characteristics desirable for studying the role of ATR in cell function. Using an epitope (FLAG) tag to detect expression of the recombinant ATR, Fig. 1A shows there is no detectable expression of the recombinant ATR protein in the absence of doxycycline. The addition of doxycycline (1 μg/ml) caused a marked induction of recombinant ATR expression. For both wild-type and kinase-dead inducible cell lines, the addition of doxycycline caused roughly a 5-fold increase in total cellular ATR relative to the endogenous ATR level as revealed by a rabbit polyclonal antibody that detects both endogenous and recombinant ATR. UV treatment of cells caused an increase in p53 levels that was proportional to the dose of UV administered, demonstrating that the p53 pathway is intact in these cells (Fig. 1C).

ATR-kd Expression, DNA Damage, and Survival—The effect of prolonged induction of ATR-wt or ATR-kd constructs was investigated in cells that were not treated with DNA damage, and cell number in the doxycycline-induced case was compared with paired cultures of the same cell line (either ATR-wt or ATR-kd) to which no doxycycline was added. Ongoing induction of ATR-wt had no effect on growth of undamaged cells over 11 passages and 40 days in culture (Fig. 2A). In contrast, after a 2-week lag, ongoing expression of ATR-kd decreased the number of viable cells to the point that none could be found after 40 days (Fig. 2A). In an identical experiment, inducible ATR-wt and ATR-kd cells generated by Cliby et al. (22) yielded the same results despite the expression of SV40 large T antigen in these other cell lines.

Colony survival assays were used to evaluate whether DNA damage selectively sensitized cells in which ATR function was inhibited by ATR-kd expression. Although induction of wild-type ATR expression had no significant effect on colony survival after any of the four treatments, ATR-kd expression decreased colony survival by roughly 10-fold in each case (Fig. 2, B and C). In the case of UV (Fig. 2B) a small difference in the number of viable cells to the point that none could be found after 40 days (Fig. 2A). In an identical experiment, inducible ATR-wt and ATR-kd cells generated by Cliby et al. (22) yielded the same results despite the expression of SV40 large T antigen in these other cell lines.

Colony survival assays were used to evaluate whether DNA damage selectively sensitized cells in which ATR function was inhibited by ATR-kd expression. Although induction of wild-type ATR expression had no significant effect on colony survival after any of the four treatments, ATR-kd expression decreased colony survival by roughly 10-fold in each case (Fig. 2, B and C). In the case of UV (Fig. 2B) a small difference in the
sensitivity of the uninduced cell lines is present with uninduced ATR-kd cells showing 10% survival at 200 J, whereas uninduced ATR-wt cells had 10% survival at 300 J. This effect may be due to low level leakiness not visible by Western blotting but detectable functionally. We have observed a similar phenomenon with caffeine sensitivity of these cells (16). These data suggest that ATR plays an essential role in rapidly dividing cells in an ongoing manner and that its role is especially critical immediately following DNA damage or an S phase arresting agent such as hydroxyurea.

*p53 Serine 15 Phosphorylation and ATR*—We used a phospho-specific antibody to assess the extent of serine 15 phosphorylation on p53 at various times after UV or IR as indicated in Fig. 3 (A and B). Similar to a prior study in SV40-transformed cells (13), our p53 wild-type cells showed a small but reproducible decrease in UV- or IR-induced serine 15 phosphorylation at roughly 120 or 180 min after radiation. In contrast, the level of p53 protein (as opposed to its phosphorylation) was essentially unaffected by ATR-kd at these time points up to 240 min after damage (Fig. 3, A and B). At 16 h after UV damage, there was no inhibitory effect of ATR-kd on p53 protein induction at any dose of UV treatment. At this later time point there was also no effect on UV or IR-induced serine 15 phosphorylation of p53 (data not shown).

*p53 DNA Binding and Transcriptional Activity*—We performed electrophoresis mobility shift assays to investigate a possible role of ATR in the induction of p53 DNA binding activity. p53 DNA binding could be observed initially about 2 h after UV treatment and peaked after 4 h (Fig. 4). In each case, there was no effect of ATR-kd on the ability of p53 to bind the labeled double-stranded oligonucleotide. An important transcriptional target of p53 in the DNA damage response pathway is p21. We used ribonuclease protection to detect p21 mRNA levels in U2OS cells overexpressing ATR-wt or ATR-kd. p21 mRNA levels increased roughly 3-fold following UV treatment in control cells, and this induction was not affected by ATR-kd (Fig. 5). These data suggest that ATR is not required for damage-induced p53 DNA binding or transcriptional activity.

*G1 Arrest*—We studied the effect of ATR-kd expression on G1 cell cycle arrest after UV-induced DNA damage by using flow cytometry of unsynchronized propidium iodide-stained cells. Nocodazole was used as a mitotic inhibitor to show that during the 18-h treatment period undamaged cells would proceed from 2N DNA content into arrest at 4N DNA content (Fig. 6). UV treatment caused a significant G1 arrest as evidenced by a persistent peak at 2N DNA content in the presence of nocodazole, which prevents mitotic cells from cycling back to G1 content. Indeed, this G1 arrest was unaffected by ATR-KD overexpression. These data demonstrate that G1 arrest occurs...
normally after DNA damage in cells that have been made sensitive to UV by ATR-kd overexpression. Taken together, we conclude that the major effect of ATR-kd is not on p53 or the G1 arrest.

**The Replication Checkpoint and ATR**—To investigate whether ATR regulates entry into mitosis after DNA damage, we used a phospho-specific antibody to assess phosphorylation of nucleolin (an event that indicates entry into mitosis (23)) in cells that had been synchronized to the G1/S boundary using a double thymidine block protocol. By 8 h after release from this G1/S block, a significant proportion of untreated or ATR-kd-expressing cells progressed into mitosis as indicated by phosphorylation of nucleolin (Fig. 7). UV-treated cells, however, were fully arrested prior to mitosis at 8 h as evidenced by the absence of phosphonucleolin. This effect of UV was significantly blocked by ATR-kd expression (Fig. 7), suggesting that ATR is involved in delaying mitotic entry after DNA damage.

Premature chromatin condensation is a hallmark of cells that have an inadequate replication checkpoint and have begun chromatin condensation, an early stage of mitosis, before completing DNA synthesis (24). In a separate set of studies we have found that ATR-kd expression markedly promotes the occurrence of premature chromatin condensation after DNA damaging treatments or replication inhibitors such as hydroxyurea (16). Fig. 8 shows that ATR-kd expression sensitizes IR- and hydroxyurea-treated cells to premature chromatin condensation as revealed by mitotic spread analysis. Expression of the G1-arresting cyclin-dependent kinase inhibitors p21 or p27 rescued ATR-kd expressing cells from PCC. In contrast, we investigated whether PCC would be promoted by inhibiting p53 function via MDM2 or E6 expression. If ATR function was necessary for p53 activation, one would predict that ATR-kd expression would inactivate p53 and that addition of MDM2 or E6 would have no effect. In fact, MDM2 or E6 expression each sharply increased the extent of PCC observed (Fig. 8), suggesting that p53 had been activated in the presence of ATR-kd expression. Taylor and Stark (25) recently reviewed several mechanisms by which p53 may promote a G2/M arrest (discussed below). Regardless of the mechanism of p53 function in preventing PCC, it is clear that ATR-kd does not significantly inhibit p53 function because of the profound additional effect of MDM2- or E6-mediated p53 inhibition. These data also indicate that ATR and p53 represent two converging pathways that cooperate to maintain genomic integrity via the replication checkpoint.

**DISCUSSION**

Several studies have shown that ATR can phosphorylate p53 on Ser15 in vitro (8–11) and in vivo (13), raising the possibility that ATR is involved in p53 regulation after DNA damage. Because of a variety of technical issues, prior studies could not examine the role of ATR in the functional regulation of p53. The data presented here are thus the first to examine the functional interactions of ATR and p53. Surprisingly, although expression of a catalytically inactive ATR caused marked sen-
sitivity to DNA damage and a transient decrease in Ser^{15} phosphorylation, ATR-kd had no effect on p53 activation by DNA damage. The simplest explanation for this finding is that ATR does not play a significant role in p53 functional activation. A related possibility is that there is functional overlap in p53 activation by multiple kinases such as ATM (26, 27), p38 (28, 29), ATR, and possibly DNA-PK (10). In such a case, inhibition of one of these could be compensated by others. In either case, the data suggest that the major role of ATR in the response to DNA damage does not involve p53 regulation.

Our data help in defining the relative roles of ATR and ATM in the response to DNA damage. There are many reasons to suspect that in some cases there may be functional overlap in the roles of ATR and ATM; both kinases phosphorylate p53 at Ser^{15} (11), they share overlapping substrate specificities (10), and ATR has been shown to rescue the radio-resistant DNA synthesis defect of ATM cells (22). Indeed, Zhou and Elledge (2) have raised the concern that overexpression of ATR-kd may in fact be mediating some of its effects by inhibition of ATM function. There are several lines of evidence that suggest this is not the case: (a) ATM is well established as important in the activation of p53 and G1 arrest (especially following ionizing radiation) (26, 27). In contrast, here we show that ATR-kd overexpression does not affect p53 activation by ultraviolet (Figs. 3–6) or ionizing radiation (Fig. 3B and data not shown). (b) In a separate study (16), we show that ATM does not play a role in the replication checkpoint that is likely a major function of ATR. In summary, it appears that in the p53/G1 checkpoint ATM plays a dominant role over ATR and that in the replication checkpoint, ATR is the relevant mediator rather than ATM. In the S phase (radio-resistant DNA synthesis) checkpoint, ATM has been well established to be involved through several mechanisms (30, 31), and ATR likely plays a role (22), perhaps through Chk-1 activation and cdc25A degradation (32).

A further intriguing distinction between ATR and ATM lies in their mechanisms of activation; ATM kinase activity increases following DNA damage (11), whereas the kinase activity of ATR measured in vitro following in vivo DNA damage is unchanged (33). The most plausible model for ATR activation is that ATR co-localizes with its relevant substrates, such as BRCA-1, following DNA damage (33) and that this damage-induced co-localization involves DNA binding (14), which has been shown to increase the kinase activity of ATR (8, 9). Given these observations of how ATR is activated in cells, we believe that expression of ATR-kd likely blocks endogenous ATR function by binding its activation partners into inactive complexes rather than by directly blocking the catalytic activity of endogenous ATR.

Our studies of premature chromatin condensation are the first to investigate the functional interactions of ATR and p53 in the G1 and replication checkpoints, which we summarize in Fig. 9. If ATR were required for p53 activation, one would expect that there would be little or no additional effect of p53 inhibition in cells expressing ATR-kd. In contrast we have found that inhibition of ATR and p53 function each independently sensitize cells to premature chromatin condensation and that the combination is more than additive (synergistic). Of note, our data suggest that ATR is more important (likely essential) in the replication checkpoint than p53 (see relative PCC rates for ATR-kd expression versus MDM2 or E6 expression). Portions of the pathway by which ATR likely functions in this checkpoint, via Chk-1 activation, have been relatively well characterized in Xenopus (14, 15) and mammalian studies (16, 34). In addition to the role of ATR in halting chromatin condensation before replication is complete, recent studies of Mec1 (the S. cerevisiae homolog of ATR) suggest ATR may also be required for progression of DNA replication (35), for stability of the replication fork (36), and for blocking late origins of replication (35).

Regarding the role of p53 in the replication checkpoint (25), there are a number of mechanisms by which this tumor suppressor can prevent cells from entering mitosis before DNA replication is complete: (a) p53 up-regulates 14-3-3-σ, which sequesters cdc25 outside the nucleus, blocking activation of mitosis promoting factor (37). (b) p53 is well established as a regulator of p21, which arrests the cell cycle in G1 and maintains a G2 arrest (38). (c) p53 induces Gadd45, which has been implicated in inducing the G2/M checkpoint (39). (d) p53 diminishes expression of Cdc2 and cyclin B1 (25). All of these p53 effects slow the cell cycle, allow time for repair, and decrease the immediate need for an ATR-mediated arrest during DNA synthesis. In contrast, p53-mediated apoptosis is not playing a role in reducing the rate of PCC observed after ATR-kd expression; p53-null status and caspase inhibition have each been shown not to prevent PCC in ATR-deficient mouse embryos (6).

Interestingly, we found that the cellular response to hydroxyurea (as well as to the more classical DNA damaging agent IR) was p53-dependent, as suggested by greater sensitivity to premature chromatin condensation upon HPV-E6 or MDM2 overexpression (Fig. 8). Others have reported that the response to hydroxyurea is dependent on p53 (40), but this has not been universally observed and may depend on the cell line.

An important implication of this work is that this level of ATR inhibition leaves p53 function fully intact, whereas the ATR/replication checkpoint is disabled. We have shown that defects in the G1 checkpoint (universally present in cancer cells) sensitize cells to lethal premature chromatin condensation by ATR inhibition (16). This observation suggests that if a more potent and specific small molecule inhibitor of ATR can be discovered it may have cancer-selective properties by sensitizing these G1 checkpoint-deficient cells to PCC. Our current results indicate that ATR inhibition does not disrupt p53 function and suggest that it may be important for an ATR inhibitor to be selective for ATR over ATM. This is because a small molecule that inhibited ATM function would cause the p53/G1 checkpoint of normal cells to be impaired, diminishing the selectivity of the inhibitor for cancer cells over normal cells.

Acknowledgments—We thank Yoichi Taya for the gift of the Serine 15 phospho-specific p53 antibody; Cyrus Vaziri for the gift of adenoviral constructs; and members of the Schreiber group for valuable discussions and assistance.
REFERENCES

1. Keith, C. T., and Schreiber, S. L. (1995) Science 270, 50–51
2. Zhou, B. B., and Elledge, S. J. (2000) Nature 408, 433–439
3. Jimenez, G., Yue, J., Rowley, R., and Subramani, S. (1992) Proc. Natl. Acad. 
   Sci. U. S. A. 89, 4952–4956
4. Weinert, T. A., Kier, G. L., and Hartwell, L. H. (1994) Genes Dev. 8, 652–665
5. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, 
   D. A., Smith, S., Uziel, T., Sfez, S., et al. (1995) Science 268, 1749–1753
6. Brown, E. J., and Baltimore, D. (2000) Genes Dev. 14, 397–402
7. de Klein, A., Muijtjens, M., van Os, R., Verhoeven, Y., Smit, B., Carr, A. M., 
   Lehmann, A. R., and Hoeijmakers, J. H. (2000) Curr. Biol. 10, 479–482
8. Hall-Jackson, C. A., Cross, D. A., Morrice, N., and Smythe, C. (1999) Oncogene 
   18, 6707–6713
9. Lakin, N. D., Hann, B. C., and Jackson, S. P. (1999) Oncogene 18, 3989–3995
10. Kim, S. T., Lim, D. S., Cannan, C. E., and Kastan, M. B. (1999) J. Biol. Chem. 
    274, 37538–37543
11. Cannan, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., 
    Appella, E., Kastan, M. B., and Siliciano, J. D. (1998) Science 281, 
    1677–1679
12. Dumaz, N., and Meek, D. W. (1999) EMBO J. 18, 7002–7010
13. Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cilby, 
    W. A., Shieh, S. Y., Taya, Y., Prives, C., and Abraham, R. T. (1999) Genes 
    Dev. 13, 152–157
14. Hekmat-Nejad, M., You, Z., Yee, M., Newport, J. W., and Cimprich, K. A. 
    (2000) Curr. Biol. 10, 1565–1573
15. Guo, Z., Kumaqi, A., Wang, S. X., and Dunphy, W. G. (2000) Genes Dev. 
    14, 2745–2756
16. Ngheim, P., Park, P. K., Kim, Y., Vaziri, C., and Schreiber, S. L. (2001) Proc. 
    Natl. Acad. Sci. U. S. A. 98, 9092–9097
17. Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y., and Prives, C. (2000) Genes Dev. 
    14, 289–300
18. Steppard, H. M., Corneille, S. I., Espiritu, C., Gatti, A., and Liu, X. (1999) 
    Mol. Cell. Biol. 19, 2746–2751
19. Yao, F., Svensjø, T., Winkler, T., Lu, M., Eriksson, C., and Eriksson, E. (1998) 
    Hum. Gene Ther. 9, 1939–1950
20. McLure, K. G., and Lee, P. W. (1998) EMBO J. 17, 3342–3350
21. Guo, N., Faller, D. V., and Vaziri, C. (2000) J. Biol. Chem. 275, 1715–1722
22. Cilby, W. A., Roberts, C. J., Cimprich, K. A., Stringer, C. M., Lamb, J. R., 
    Schreiber, S. L., and Friend, S. H. (1998) EMBO J. 17, 159–169
23. Anderson, H. J., de Jong, G., Vincenti, I., and Roberge, M. (1998) Exp. Cell Res. 
    238, 488–502
24. Schlegel, R., and Pardee, A. B. (1986) Science 232, 1264–1266
25. Taylor, W. R., and Stark, G. R. (2001) Oncogene 20, 1803–1815
26. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, P., Jacks, T., Walsh, W. V., 
    Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. (1992) Cell 71, 
    587–597
27. Khanna, K. K., and Lavin, M. F. (1993) Oncogene 8, 3307–3312
28. Bulavin, D. V., Saito, S., Hollandier, M. C., Sakaguchi, K., Anderson, C. W., 
    Appella, E., and Fornace, A. J., Jr. (1999) EMBO J. 18, 6845–6854
29. Huang, C., Ma, W. Y., Maxiner, A., Sun, Y., and Dong, Z. (1999) J. Biol. Chem. 
    274, 12229–12235
30. Falck, J., Mailand, N., Syllas, R. G., Bartek, J., and Lukas, J. (2001) Nature 
    410, 842–847
31. Lim, D. S., Kim, S. T., Xu, B., Maser, R. S., Lin, J., Petrini, J. H., and Kastan, 
    M. B. (2000) Nature 404, 613–617
32. Mailand, N., Falck, J., Lukas, C., Syllas, R. G., Welecker, M., Bartek, J., and 
    Lukas, J. (2000) Science 288, 1425–1429
33. Shibetta, R. S., Cortez, D., Brumbaugh, K. M., Scully, R., Livingston, D., 
    Elledge, S. J., and Abraham, R. T. (2000) Genes Dev. 14, 2989–3002
34. Liu, Q., Gunuku, S., Cui, X. S., Matsusuka, S., Cortez, D., Tamai, K., Luo, G., 
    Carattini-Rivera, S., DeMayo, F., Bradley, A., Donehower, L. A., and 
    Elledge, S. J. (2000) Genes Dev. 14, 1448–1459
35. Tercero, J. A., and Diffley, J. F. (2001) Nature 412, 553–557
36. Lopez, M., Cota-Hamusino, C., Pollicioli, A., Liberi, G., Plevani, P., Musi-Falconi, 
    M., Newlon, C. S., and Feinian, M. (2001) Nature 412, 557–561
37. Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W., and Vogelstein, B. 
    (1999) Nature 401, 616–620
38. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., 
    Sedivy, J. M., Kinzler, K. W., and Vogelstein, B. (1998) Science 282, 
    1497–1501
39. Wang, X. W., Zhan, Q., Courten, J. D., Khan, M. A., Kontny, H. U., Yu, L., 
    Hollandier, M. C., O’Connor, P. M., Fornace, A. J., Jr., and Harris, C. C. 
    (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3706–3711
40. Taylor, W. R., Agarwal, M. L., Agarwal, A., Stacey, D. W., and Stark, G. R. 
    (1999) Oncogene 18, 283–295
ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint

Paul Nghiem, Peter K. Park, Yong-son Kim, Bimal N. Desai and Stuart L. Schreiber

J. Biol. Chem. 2002, 277:4428-4434.
doi: 10.1074/jbc.M106113200 originally published online November 15, 2001

Access the most updated version of this article at doi: 10.1074/jbc.M106113200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 40 references, 24 of which can be accessed free at http://www.jbc.org/content/277/6/4428.full.html#ref-list-1